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Niemann-Pick disease type C (NPC) is a fatal, autosomal recessive lipidosis characterized by lysosomal accumulation
of unesterified cholesterol and multiple neurological symptoms, such as vertical supranuclear ophthalmoplegia,
progressive ataxia, and dementia. More than 90% of cases of NPC are due to a defect in Niemann-Pick C1 (NPC1),
a late endosomal, integral membrane protein that plays a role in cholesterol transport or homeostasis. Biochemical
diagnosis of NPC has relied on the use of patient skin fibroblasts in an assay to demonstrate delayed low-density
lipoprotein (LDL)–derived cholesterol esterification and a cytological technique—filipin staining—to demonstrate
the intracellular accumulation of cholesterol. A small percentage of patients, referred to as “NPC variants,” present
with clinical symptoms of NPC but show near-normal results of these biochemical tests, making laboratory con-
firmation of NPC disease problematic. Here, we demonstrate that NPC-variant fibroblast samples can be detected
as sphingolipid storage disease cells, using a fluorescent sphingolipid analog, BODIPY-lactosylceramide. This lipid
accumulated in endosomes/lysosomes in variant cells preincubated with LDL cholesterol but targeted to the Golgi
complex in normal cells under these conditions. The reproducibility of this technique was validated in a blinded
study. In addition, we performed mutation analysis of the NPC1 gene in NPC variant and “classical” NPC cell
samples and found a high incidence of specific mutations within the cysteine-rich region of NPC1 in variants. We
also found that 5 of the 12 variant cell samples had no apparent defect in NPC1 but were otherwise indistinguishable
from other variant cells. This is a surprising result, since, in general, ∼90% of patients with NPC possess defects
in NPC1. Our findings should be useful for the detection of NPC variants and also may provide significant new
insight regarding NPC1 genotype/phenotype correlations.
Introduction
Niemann-Pick C (NPC [MIM 257220]) disease is a fatal,
autosomal recessive, neurovisceral disorder with an es-
timated prevalence of ∼1:150,000 in Western Europe
and a much higher prevalence in some geographically
isolated populations (e.g., French Acadians of Nova Sco-
tia and Hispanics of southern Colorado) (Winsor and
Welch 1978; Carstea et al. 1997; Millat et al. 1999;
Patterson et al. 2001). Biochemically, NPC is character-
ized by extensive lysosomal accumulation of unesterified
cholesterol in many tissues, as well as lysosomal storage
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of sphingolipids in some tissues (e.g., liver and brain)
(Vanier 1999; Patterson et al. 2001). Most individuals
with NPC possess a defect in Niemann-Pick C1 (NPC1),
a 1,278–amino acid, integral membrane protein which
has been localized to late endosomes (Carstea et al.
1997; Neufeld et al. 1999). Although the function of the
NPC1 protein is not fully understood, it is believed to
be involved in the intracellular transport of low-density
lipoprotein (LDL)–derived free cholesterol (Neufeld et
al. 1999; Cruz et al. 2000; Lange et al. 2000). Fewer
than 10% of patients with NPC are not defective in
NPC1 but can be shown, by cell fusion and/or linkage
studies, to fall into a second complementation group,
referred to as “NPC2” (MIM 601015). NPC2 has re-
cently been shown to be a result of mutations in HE1,
a ubiquitously expressed, soluble lysosomal protein
which binds cholesterol (Naureckiene et al. 2000). Pa-
tients with NPC1 and those with NPC2 are indistin-
guishable, both clinically and in terms of the standard
biochemical tests for NPC (see below) (Vanier et al.
1996; Patterson et al. 2001).
NPC has protean clinical presentations, ranging from
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fetal ascites to slowly progressive neurodegeneration in
adult life (reviewed by Patterson et al. [2001]). The nerv-
ous system, bone marrow, liver, and lungs may all be
directly impaired by the disease process. Although the
disease may present in any fashion along this temporal
and phenotypic continuum, it is helpful for the clinician
to distinguish some common patterns. The classic pre-
sentation is with variable hepatosplenomegaly and ver-
tical supranuclear gaze palsy, ataxia, dystonia, and de-
mentia in late childhood (“juvenile NPC”), culminating
in death before age 20 years (Patterson et al. 2001). A
second group (“infantile NPC”) presents with cholesta-
sis and/or liver failure early in infancy, and patients die
before age 2 years. Some patients present primarily with
cognitive or psychiatric disturbances in adulthood
(“adult-onset NPC”) with a slower progressive neurod-
egeneration. Patients with atypical presentation (i.e.,
those expressing only fragments of the classical phe-
notype) may be the most difficult to recognize (e.g., see
Uc et al. 2000) but also may be the most amenable to
potential therapies and may, therefore, benefit substan-
tially from early, accurate diagnosis.
The standard biochemical assays for NPC utilize pa-
tient fibroblasts and consist of (i) a demonstration of
impaired esterification of LDL-derived cholesterol and
(ii) characteristic intense, punctate, cytoplasmic staining
of cells with filipin, a fluorescent polyene antibiotic
which binds to free cholesterol, to show the accumu-
lation of free cholesterol in cells (Morris and Carstea
1998; Patterson et al. 2001). However, although 180%
of NPC cases can be distinguished by cholesterol ester-
ification rates of !10% of normal cells and obvious
filipin staining, a minority of patients who present with
classical clinical symptoms of NPC (e.g., supranuclear
vertical gaze palsy, progressive neurological decline)
exhibit a “variant” biochemical phenotype, with inter-
mediate-to-normal cholesterol-esterification rates and
less-definitive filipin staining (Vanier et al. 1991; Vanier
et al. 1996). Thus, the diagnosis of NPC in these patients
is difficult to confirm by existing methods, and the
clinician must rely on a combination of clinical and
ultrastructural data.
Throughout the length of the NPC1 protein in pa-
tients with NPC, 190 different deleterious mutations
have been reported to occur, including point mutations
and frameshifts leading to truncation of the protein
(Carstea et al. 1997; Greer et al. 1999; Millat et al.
1999; Yamamoto et al. 1999; Ioannou 2000; Snow et
al. 2000). The most commonly found NPC1 mutation,
I1061T, has been shown to occur with relatively high
frequency in patients of western European descent, and
it generally correlates with a juvenile clinical phenotype
with classical low cholesterol-esterification rates (Millat
et al. 1999). A second mutation, G992W, is responsible
for the Niemann Pick D (NPD) subtype of NPC disease
in patients of common ancestry from southwestern
Nova Scotia (Greer et al. 1998). Patients with NPD
usually first present with clinical symptoms during the
juvenile years, but their cholesterol-esterification rates
are intermediate between those of classical NPC cells
and normal fibroblasts (Sidhu et al. 1993; Jan and Cam-
field 1998). Other than these data, no significant cor-
relations have been reported between the clinical pre-
sentation of the disease and either biochemical analyses
or the occurrence of different NPC1 mutations among
patients with NPC. In particular, nothing is known
about whether the variant phenotype is dictated by spe-
cific NPC1 mutations or is due to offsetting effects of
other aspects of the patient’s genetic background.
We previously described a broad screening assay for
detection of multiple sphingolipid storage diseases
(SLSDs), including NPC (Chen et al. 1999). This assay
was based on the observation that a fluorescent sphin-
golipid analog (BODIPY-lactosylceramide [LacCer]) is
transported to the Golgi apparatus in normal fibroblasts
after endocytosis but is targeted to endosomes/lyso-
somes in cell samples from patients with an SLSD. This
mistargeting of BODIPY-LacCer was found to be di-
rectly related to accumulation of cellular free cholesterol
(Puri et al. 1999). Here, we have modified this technique
so that it will detect NPC variants, in addition to pa-
tients with classical NPC. In addition, we performed
mutational analysis of the NPC1 protein in variant and
classical NPC samples and found that most mutations
identified in variant samples were point mutations
within the “cysteine-rich region” (Greer et al. 1999;
Watari et al. 2000) of NPC1.
Patient Samples and Methods
Cells and Culture Conditions
All normal and one NPC (GM3123) human skin fi-
broblasts were obtained from the Coriell Institute for
Medical Research. Other NPC human skin fibroblasts
were from the NPC Cell Repository of the Division of
Laboratory Genetics at the Mayo Clinic in Rochester,
MN. Many of these samples were originally collected at
the Developmental and Metabolic Neurology Branch,
National Institute of Neurological Disorders and Stroke
(NINDS). Patient samples were used anonymously and
with consent for research purposes, under a protocol
approved by the Mayo Clinic internal review board.
NPC patient samples with cholesterol esterification rates
1800 pmol/mg protein/6 h and nondefinitive filipin stain-
ing were defined as “variants.” Additional NPC samples
with cholesterol esterification rates of !500 pmol/mg
protein/6 h were defined as “classical” NPC samples.
These definitions are based on those originally used by
Vanier et al. (1991).
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Cells were typically grown in Eagle’s minimum essen-
tial medium (EMEM) supplemented with 10% fetal bo-
vine serum (FBS) (referred to hereafter as basal medium)
as described (Martin and Pagano 1994). For some ex-
periments, cells were incubated inmedium supplemented
with up to 150 mg/ml LDL (Sigma) for 24 h before in-
cubation with BODIPY-LacCer or fixation for filipin and
NPC1 immunostaining. All microscopy experiments
were performed on cells grown to 30%–60% confluence
on acid-etched 25-mm glass cover slips.
Esterification of LDL-Derived Cholesterol
Cholesterol esterification was performed essentially as
described by Vanier et al. (1988). Briefly, cells seeded at
a density of 5–10#105 cells in a 75 mm2 flask were
maintained in McCoy’s 5A medium supplemented with
10% FBS and then were incubated at 37C for 4 d in
fresh medium supplemented with 10% lipoprotein-de-
ficient serum (LPDS). Cholesterol esterification was in-
itiated by the addition of freshmedium containing [3H]o-
leate (100 mmol/l in BSA solution),50 mg/ml of LDL.
After 6 h, lipids were extracted and were separated by
thin-layer chromatography, and the radioactivity in cho-
lesterol ester was determined by scintillation counting.
Fluorescence Microscopy and BODIPY-LacCer Labeling
BODIPY-LacCer was custom synthesized as described
(Martin and Pagano 1994). Cells were incubated with
5 mMBODIPY-LacCer/BSA for 45min at 37C in culture
medium containing 1% FBS, were washed, were incu-
bated in medium with 1% FBS for an additional 1 h at
37C, and then were back exchanged with 5% BSA to
remove cell-surface fluorescence (Martin and Pagano
1994; Chen et al. 1999). Fluorescence microscopy was
performed using an Olympus IX70 microscope. Fluo-
rescence micrographs for each experiment were exposed
and printed identically and are representative of 80%
of the cells in a given experiment. Quantitation of BOD-
IPY-LacCer in Cascade blue dextran-(Sigma) positive ly-
sosomes of individual cells was determined by ratio im-
aging (Pagano et al. 2000). Filipin staining and NPC1
immunostaining of formaldehyde-fixed cells were per-
formed as described elsewhere (Neufeld et al. 1999).
Cholesterol Challenge and Blinded Study
Normal, classical NPC, and NPC variant fibroblasts
were grown on glass cover slips, as described above. The
cells were incubated for 24 hwith 0–150 mg/ml of human
LDL and then were pulse-labeled with BODIPY-LacCer,
as described above. For the blinded study, coded samples
of normal, variant, and classical NPC cells preincubated
in basal mediumwith or without LDLwere pulse-labeled
with BODIPY-LacCer. Observers were then asked to
score, in a blinded study, paired coded samples (the same
cell sample with or without LDL) as either normal (Golgi
labeling) or NPC (punctate labeling), on the basis of
LacCer targeting patterns observed by fluorescence
microscopy.
Complementation Analysis
Complementation analysis was performed on cell lines
to determine whether the underlying genetic defect was
in the NPC1 gene or NPC2 gene. Testing was performed
as previously described (Vanier et al. 1996), using filipin
staining to assess whether biochemical correction was
present in fused cells. Control NPC1 and NPC2 cell lines
had previously been determined to be in these comple-
mentation groups by analysis performed at the Devel-
opmental and Metabolic Neurology Branch at NINDS
(Vanier et al. 1996).
NPC1 Mutation Detection
Genomic DNA was isolated from fibroblast cell lines,
using the Puregene extraction kit (Gentra Systems).
DNA samples were screened for mutations in NPC1 by
conformation-sensitive gel electrophoresis (CSGE) and
DNA sequencing. CSGE was utilized for initial screening
of NPC1 exons and adjacent intronic sequences (Korkko
et al. 1998; Markoff et al. 1998). To increase efficiency
of the CSGE analysis, multiplex PCR (with primers to
three different exons per multiplex) was used to generate
products for CSGE (Snow et al. 2000). Homozygous
alterations were detected by mixing PCR products from
cell lines with PCR products from a normal control prior
to heteroduplex formation and electrophoresis. Of the
25 NPC1 exons, 4 (1, 12, 14, and 17), which could not
be analyzed by CSGE because repetitive sequences
within the PCR products caused the formation of com-
plex banding patterns, were analyzed by DNA sequenc-
ing. DNA sequencing was also used to analyze all sam-
ples with novel CSGE banding patterns and other
samples and exons as indicated in the text. Cycle se-
quencing of PCR products utilized ABI Prism BigDye
Terminator chemistry (PE Biosystems), an ABI Prism 377
Sequencer (PE Biosystems), and SEQUENCHER soft-
ware (Gene Codes) for data analysis.
Southern blot assays using genomic DNA digested
with BglII and HindIII (in separate reactions) were used
to test for large deletions in some samples that were in
the NPC1 complementation group but did not have mu-
tations detected by the preceding methods. Probes used
in Southern blot hybridization were generated by PCR
of each of the NPC1 exons and were labeled with [32P]-
dCTP using the HighPrime random prime labeling kit
(Roche Molecular Biochemicals).
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Figure 1 LDL-derived cholesterol-esterification rates in the NPC
subtypes. Esterification rates of LDL-derived cholesterol in normal,
NPC variant, and classical NPC fibroblasts grown in lipoprotein-de-
ficient serum were measured using [3H]oleate (see Patient Samples and
Methods). Values are means of triplicate measurements of individual
samples.
Results
Cholesterol Esterification Rates in NPC Fibroblast
Samples
We used a subset of NPC patient fibroblast samples
from the Mayo Clinic NPC cell repository. All samples
were obtained from patients with clinical symptoms con-
sistent with NPC disease. Among 1200 fibroblast sam-
ples derived from patients with NPC, we identified 13
samples (referred to henceforth as “variants” and in-
cluding one pair of siblings) with cholesterol esterifica-
tion rates 1800 pmol/mg of protein/6 h and nondefinitive
filipin staining (see fig. 4A). An additional 34 samples,
including three pairs of siblings, with cholesterol ester-
ification rates of !500 pmol/mg of protein/6 h, were
chosen from the cell repository as representative samples
of classical NPC. A scattergram of cholesterol-esterifi-
cation values of all variant, classical NPC, and normal
fibroblasts used for our study is shown in fig. 1. This
figure illustrates how cholesterol-esterification values of
variants (range 1,161–6,561 pmol cholesterol ester/mg
of protein/6 h; mean standard error [SE]p 2,235
420) overlap with the range for normal cells (range
2,803–7,200; mean  SE p 5,448  934), making
cholesterol-esterification assays insufficient for confirm-
ing a diagnosis of NPC in these patients.
Detection of NPC Variants by a Sphingolipid-Targeting
Assay
When we applied our original protocol for detection
of SLSD cells, BODIPY-LacCer was targeted to the Golgi
complex in normal human skin fibroblasts but was
transported to endosome/lysosomes in classical NPC cell
samples (fig. 2), which is consistent with our recent stud-
ies (Chen et al. 1999; Puri et al. 1999). All variant cell
samples, however, displayed Golgi targeting of BODIPY-
LacCer that was indistinguishable from that in normal
cells (fig. 2 and data not shown).
We recently found that altered BODIPY-LacCer traf-
ficking in SLSD cells is caused by elevated free choles-
terol in these cells (Puri et al. 1999). The lack of lyso-
somal accumulation of BODIPY-LacCer in variant cells
suggests that, under basal cell culture conditions (growth
in media with 10% fetal bovine serum [FBS]), cholesterol
levels in variants are similar to those in normal fibro-
blasts. Indeed, filipin staining in NPC variants is often
similar to that in normal cells (Vanier et al. 1991; Pat-
terson et al. 2001). We hypothesized (i) that NPC variant
cells challenged by growth medium with excess LDL
cholesterol may exhibit altered distribution or elevated
levels of cholesterol compared with those in normal cells
and (ii) that this would be reflected in altered BODIPY-
LacCer targeting.
We first examined the dose-dependent effects of LDL
on BODIPY-LacCer distribution in variant, classical
NPC, and normal fibroblasts, using a quantitative ap-
proach. Cell samples were incubated for 24 hwith 0–150
mg/ml of LDL (without prior lipid depletion) and with
2 mg/ml fluorescent blue dextran, a probe that accu-
mulates in lysosomes after endocytosis (Koval and
Pagano 1990). The cells were then pulse labeled with
BODIPY-LacCer, and the relative concentration of BO-
DIPY-LacCer in dextran-positive vesicles was calculated
by red/green ratio imaging (Chen et al. 1997, 1999; Pa-
gano et al. 2000). At 150 mg/ml, LDL dramatically in-
creased the extent of colocalization of BODIPY-LacCer
with dextran-labeled lysosomes in NPC variant fibro-
blasts but had little effect on normal or classical NPC
cells (fig. 3).
After treatment with 150 mg/ml of LDL, filipin staining
showed an alteration, in the distribution of the intra-
cellular free-cholesterol level in variant cells, to a pattern
similar to that in classical NPC cells (fig. 4A); LDL treat-
ment had little effect on filipin staining in normal or
classical NPC cells (fig. 4A). The effect of LDL treatment
on BODIPY-LacCer localization in variant cells was
more striking; excess LDL shifted the distribution of
BODIPY-LacCer from the Golgi to punctate structures
in variant cells but had little effect on the Golgi labeling
of normal cells or the punctate labeling of classical NPC
cells (fig. 4B). This cholesterol-induced alteration in
BODIPY-LacCer targeting was observed in all 13 variant
cell samples studied (data not shown); the cholesterol
challenge had no effect on the Golgi targeting of BOD-
IPY-LacCer in all normal fibroblast samples examined
( ).np 6
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Figure 3 Selective dose-dependent LDL-induced lysosomal tar-
geting of BODIPY-LacCer in NPC variants. Normal, variant, and clas-
sical NPC fibroblasts were preincubated overnight in culture medium
with 10% FBS plus 0–150 mg/ml of LDL, along with 2 mg/ml Cascade
blue dextran, a lysosomal marker. Cells were then pulse labeled with
BODIPY-LacCer, as in figure 2. Blue, green, and red images of the
same cells were acquired under the fluorescence microscope, and the
amounts of BODIPY-LacCer in dextran positive-lysosomes were de-
termined by red/green ratio imaging (Puri et al. 1999; Pagano et al.
2000). Each data point was obtained using multiple cultures of a single
representative patient cell sample. Values are the mean  SE for
LacCer accumulation in the lysosomes of four or more cells (1100
lysosomes analyzed per cell). LDL added to culture media at 0, 50,
100, and 150 mg LDL protein/ml corresponded to∼0.04,∼0.40,∼0.77,
and ∼1.14 mg total cholesterol per ml of media, respectively.
Figure 2 BODIPY-LacCer targeting in normal, variant, and classical NPC cells. Living NPC fibroblasts on glass cover slips were pulse-
labeled with BODIPY-LacCer for 45 min at 37C and were observed by fluorescence microscopy (see Patient Samples and Methods). Images
are representative of 180% of cells observed for each experiment. Note that BODIPY-LacCer was targeted to the Golgi apparatus in both
normal and NPC variant cells but was concentrated in punctate structures in classical NPC cells. Bar p 10 mm. G p Golgi complex.
Blinded Study of Sphingolipid Trafficking Assay
We conducted a blinded study to validate the useful-
ness of the modified BODIPY-LacCer targeting assay to
detect NPC variants. Trained observers were asked to
examine the distribution of BODIPY-LacCer by fluores-
cence microscopy in paired samples (the same cell sample
preincubated with or without LDL) of normal, classical
NPC, and NPC variant cells and to score the coded
samples as either normal or NPC on the basis of the
intracellular distribution of BODIPY-LacCer. As shown
in table 1, the variant samples were scored as NPC sam-
ples in only 4 of 23 trials without LDL treatment, but
were successfully detected as NPC in 22 of 23 trials with
LDL. The frequency of successful detection of classical
NPC cells was also increased with LDL, from 23 to 25
of 26 trials (table 1). When the modified BODIPY-
LacCer assay with LDL was used, there were no false
positives and only 2 false negatives in 47 trials. Thus,
the technique should be useful for detection of NPC
variants and may also increase the probability of detec-
tion of classical NPC in patient samples.
NPC1 Mutation Analysis of NPC Subtypes
The results of NPC1 mutation analysis of individual
NPC cell lines are shown in table 2 along with choles-
terol-esterification rates for these samples. In 12 variant
cell lines (NPC patient samples with cholesterol-esteri-
fication rates of 1800 pmol cholesterol/mg protein/6 h)
from unrelated patients, two NPC1 mutations were
found in 5 fibroblast samples, and single mutations were
identified in 2 additional samples. For the five fibroblast
Figure 4 LDL-challenge alteration of intracellular cholesterol distribution and BODIPY-LacCer transport in NPC variant fibroblasts.
Normal, NPC variant, and classical NPC fibroblasts were incubated in culture medium  150 mg/ml of LDL for 24 h before filipin staining
or incubation with BODIPY-LacCer. A, After fixation, cells were labeled with 50 mg/ml filipin (Neufeld et al. 1999), a polyene antibiotic which
permeabilizes cells and binds to free cholesterol. Note that LDL treatment resulted in a greater alteration in intracellular cholesterol distribution
in NPC variant cells than in normal cells. B, After treatment with and without LDL, cells were pulse labeled with BODIPY-LacCer, as in figure
2. LDL treatment shifted the BODIPY-LacCer targeting in variant cells from the Golgi apparatus to punctate structures but had little effect in
normal or classical NPC cells. For each experiment, all micrographs were exposed and printed identically. Bar p 10 mm.
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Table 1
Blinded Study of LacCer Trafficking Screening Assay Performed
with or without LDL
SAMPLE
CATEGORY
(NO. OF UNIQUE
SAMPLES)
TOTAL
TRIALS
NO. OF TRIALS SCORED
CORRECTLY
Without LDL With LDL
Normal (5) 23 23 23
NPC:
Variant (6) 23 4 22
Classical (6) 26 23 25
NOTE.—Normal, variant NPC, and classical NPC human skin fi-
broblast samples grown on glass cover slips were incubated overnight
in basal medium with or without 150 mg/ml of LDL. Cell samples
were then pulse labeled with BODIPY-LacCer, as described in Patient
Samples and Methods. Coded samples were observed under the flu-
orescence microscope and scored either as normal (Golgi staining) or
as SLSD-like (i.e., NPC; punctate staining). After breaking the sample
code, the numbers of trials found to be scored correctly as either
normal or NPC was determined. For each sample category, multiple
replicates from each of several unique samples were tested (numbers
in parentheses indicate the number of individual control or patient cell
samples).
samples in which two mutant alleles were identified, all
samples were compound heterozygotes, and 9 of 10 mu-
tations were missense point mutations. For the two ad-
ditional fibroblast samples in which only one mutation
was found, one was a missense mutation and the other
was a frameshift mutation (table 2). Of 12 mutant alleles
found among variant samples, 7 (58%) occurred be-
tween amino acids 940 and 1007 (table 2) in the cys-
teine-rich region of NPC1 (amino acids 854–1014
[Greer et al. 1999; Watari et al. 2000]). In five additional
variant samples, no NPC1 mutations were found, either
by CSGE screening or by DNA sequencing of all 25
NPC1 exons. The identification of such a high percent-
age of non-NPC1 cases among variants was surprising,
because, in general, ∼90% of patients with NPC are
reported to possess NPC1 mutations (Patterson et al.
2001). In addition, mutations have been found in 190%
of NPC1 alleles from ∼200 NPC cell lines in the Mayo
NPC cell repository (K.S., unpublished data). One of the
variant cell samples in which no NPC1 mutations were
detected (sample V9 in table 2) was determined to be in
the NPC2 complementation group. Complementation
studies (based on correction of high filipin staining in
heterokaryons) could not be interpreted with confidence
by use of the other variant samples lacking in NPC1
mutations, because the normal-like filipin staining in
these cells made assessments of correction in fused cells
nondefinitive.
Among 31 unrelated classical NPC samples, 38 dif-
ferent DNA alterations were found, including missense,
frameshift, and splicing mutations that occurred
throughout much of the NPC1 gene (table 2). The
I1061T substitution was found to be the most common
mutation among classical NPC cases, occurring in 11 of
62 unrelated alleles in nine unrelated patients. In con-
trast, this mutation was not identified in any of the var-
iant samples. The high occurrence of I1061T among
classical NPC patient samples is similar to previously
published findings and is consistent with the idea that
this mutation leads to a classical NPC phenotype (Millat
et al. 1999). In contrast with the findings for the variant
samples, only 10 of 62 NPC1mutations in classicalNPC
samples occurred within the cysteine-rich region. Four
mutations in this region that occurred among variant
patients (D948N, R958Q, R978C, and S1004L) were
not present in any classical patient samples (table 2).
Mutations in the cysteine-rich region found in both var-
iant and classical samples (S940L and P1007A) occurred
in combinations with different mutations between the
two phenotypic types, suggesting that interactions be-
tween both alleles play a role in determining the classical
versus variant phenotype. From these few samples, it
cannot be determined with certainty if the variant and
classical phenotypes are determined entirely by specific
combinations of NPC1 mutations or if other individual
genetic differences also play a role. However, for four
pairs of siblings, identical mutations resulted in the same
NPC subtype classification (table 2), suggesting a strong
influence of specific mutations on NPC phenotypes.
Discussion
We studied the feasibility of using BODIPY-LacCer traf-
ficking in human skin fibroblasts to detect NPC variants.
We found that, under basal conditions (cells cultured in
10% FBS), NPC variant samples were indistinguishable
from normal fibroblasts in their ability to target BO-
DIPY-LacCer to the Golgi apparatus. However, over-
night treatment with LDL shifted the distribution of BO-
DIPY-LacCer in NPC variant samples from the Golgi to
punctate, endosomal structures typically seen in classical
NPC and many other SLSDs (Chen et al. 1999) but did
not affect the Golgi targeting of BODIPY-LacCer in nor-
mal fibroblasts. We validated the reproducibility of this
modified assay in a blinded study which demonstrated
that BODIPY-LacCer trafficking (with the LDL modi-
fication) detected variant samples as NPC in 195% of
total trials. Finally, we performed NPC1 mutational
analysis in variant and classical samples and found that
specific mutations within the cysteine-rich region of
NPC1 are correlated with the variant phenotype.
We have demonstrated elsewhere that BODIPY-
LacCer trafficking is altered in many SLSDs (NPC, Nie-
mann Pick A and B, prosaposin deficiency, Fabry dis-
ease, metachromatic leucodystropy, GM1 and GM2
gangliosidoses, and mucolipidosis type IV), and we have
Table 2
NPC1 Mutations Found for Cell Lines with Variant and Classical Biochemical Phenotypes
CELL LINE
MUTATIONS
CHOLESTEROL ESTERIFICATION
(pmol cholesterol/mg protein/6 h)Allele 1 Allele 2
Variant:
V1 T137M D948N 1,830
V2 P237S S1004L 1,498
V3 S940L R978C 1,161
V4a R958Q P1007A 1,726; 3,716
V5 P1007A IVS21(-10)delTCC 1,867
V6 P237S None found 1,498
V7 2336insT None found 1,692
V8 None found None found 1,532
V9b None found None found 1,263
V10 None found None found 3,352
V11 None found None found 6,561
V12 None found None found 1,370
Classical:
C1 Q92R 394delC 0
C2 P237S I1061T 159
C3 D242N S940L 0
C4 G248V M1142T 48
C5 P401T I1061T 145
C6 R404Q D874V 16
C7 R404Q R404Q or deletionc 41
C8 1628delC 1628delC or deletionc 0
C9 E612D 1628delC 0
C10 S652W I1061T 2
C11 S652W IVS9(1)GrC 30
C12 R789C V1023G 187
C13 Y825C 451-452delAG 10
C14a D874V Y890X 44; 110
C15 D874V del1271 25
C16 P888S R1186H 30
C17 Q921X I1061T 24
C18 L929P 3322insG 198
C19a S940L 688del6bp 131; 303
C20 D944N P237S, IVS23(3)GrC 46
C21 R958X R958X or deletionc 145
C22 C976R E1089K 71
C23 P1007A Deletiond 365
C24 I1061T 636delT 0
C25 I1061T I1061T 29
C26 I1061T I1061T 43
C27a I1061T NII50K 0; 0
C28 I1061T V1165M 300
C29 N1156S R1186H 127
C30 R1186H R1186H or deletionc 0
C31 E1189G 3135insG 32
NOTE.—Underlines indicate missense mutations within the cysteine-rich region (amino acids
857–1015) of NPC1 (Greer et al. 1999; Watari et al. 2000).
a Identical mutations were found for two affected siblings. Esterification values are individual results
for each sibling.
b Found by complementation studies to be in the NPC2 complementation group.
c Possible null allele; parental samples were not available and Southern blots were either not infor-
mative or not performed.
d A deletion in one allele was demonstrated by Southern blotting.
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proposed this technique as a broad initial screening as-
say for detection of SLSDs (Chen et al. 1999). We sub-
sequently determined that the altered trafficking of
BODIPY-LacCer in SLSD cells results from an accu-
mulation of excess intracellular free cholesterol, either
due to a primary defect (e.g., NPC) or secondary to the
accumulation of sphingolipids in cells deficient in spe-
cific lysosomal hydrolase activities (e.g., Niemann-Pick
A and gangliosidoses) (Puri et al. 1999).
Here, we found that, unlike classical NPC fibroblasts,
all of the NPC variant cells that we tested exhibited no
defect in BODIPY-LacCer targeting when cultured in
basal medium. These results suggest that, under these
conditions, variant cells have little intracellular accu-
mulation of LDL-derived cholesterol, which is consis-
tent with low-to-intermediate filipin staining in these
cells (e.g., see fig. 4A). However, given the reportedmul-
tiple defects in cholesterol homeostasis reported for
NPC cells (Pentchev et al. 1987; Patterson et al. 2001),
we hypothesized that challenging variant cells with ex-
cess exogenous LDL would induce an NPC-like phe-
notype without perturbing normal cells. We optimized
the LDL treatment and found a dosage that selectively
induced altered BODIPY-LacCer trafficking in variant
(but not normal) cells. It should be noted that, of the
cell types that we have studied, classical NPC cells and
other storage-disease cells (noted above) all show ab-
normal BODIPY-LacCer trafficking, even when assayed
in basal medium, whereas normal cells do not shift to
a SLSD-like pattern of BODIPY-LacCer targeting, even
when challenged overnight with 150 mg/ml of LDL.
Thus, the shift from normal trafficking of BODIPY-
LacCer to abnormal, SLSD-like trafficking, on challenge
with cholesterol, appears to be specific to NPC variant
cells (fig. 4B). We propose that the BODIPY-LacCer
trafficking assay, modified by the cholesterol challenge,
may be useful for the confirmation of a diagnosis of
NPC in the case of variants. Our limited blinded study
confirmed the potential usefulness of the method. How-
ever, more-extensive trials of this assay are required for
full evaluation of its value as a diagnostic procedure for
NPC variants. We also tested the modified BODIPY-
LacCer–trafficking assay as a possible means of detec-
tion of carriers of NPC. However, trials with several
obligate heterozygote parents of patients with classical
NPC showed no perturbations in BODIPY-LacCer traf-
ficking, before or after cholesterol treatment (data not
shown), suggesting that this technique will not be useful
for the detection of NPC heterozygotes.
Defective cholesterol transport is accepted as a hall-
mark of the cell-biological pathology in NPC disease
(Patterson et al. 2001). The selective response by vari-
ants to LDL-cholesterol supports the concept that var-
iants have diminished capacity for cholesterol transport
and are part of the continuum of phenotypes in theNPC
disease complex. In addition to an impairment in cho-
lesterol trafficking, patients with NPC exhibit storage
of sphingolipids in visceral organs and the brain, and
NPC cells in culture also accumulate sphingolipids
(Vanier 1983; Walkley 1995; Vanier 1999; Patterson et
al. 2001). Thus, a possible direct role for the NPC1
protein in sphingolipid transport has been proposed
(Neufeld et al. 1999; Vanier 1999). Indeed, in a recent
study, anti-glycosphingolipid antibodies were used to
demonstrate the presence of several endogenous gly-
cosphingolipids (including LacCer) within the NPC1-
containing endosomal compartment in normal fibro-
blasts, as well as the absence of these lipids from this
compartment in NPC cells (Zhang et al. 2001). Al-
though we demonstrated elsewhere that the regulation
of targeting of BODIPY-LacCer between the Golgi or
punctate endosomes in SLSD cells in general is closely
linked to intracellular cholesterol levels and/or distri-
bution (Puri et al. 1999), we cannot rule out the pos-
sibility that, in the case of classical or variant NPC
fibroblasts, mutations in the NPC1 protein have a more
direct effect on the intracellular transport of BODIPY-
LacCer.
We found a total of 49 different NPC1 mutations
among the variant and classical NPC samples that were
analyzed. Genotype-phenotype correlations among
these data are difficult, because of the large number of
private mutations and because most of the samples were
found to be heteroallelic. However, several observations
of genotype-phenotype correlation among certain mu-
tations may be significant. Among the variant samples
for which we detected NPC1 mutations, we found a
high incidence of point mutations between amino acids
940–1007 within the NPC1 cysteine-rich region (Greer
et al. 1999). An association betweenmissensemutations
in this region and the NPC variant phenotype has also
been recently noted elsewhere (Vanier andMillat 2000).
The NPC1 cysteine-rich region contains eight cysteine
residues that are conserved between mammals, Cae-
norhabditis elegans and yeast (Greer et al. 1999) and
forms part of a hydrophilic loop that has a luminal
orientation within the endosome (Davies and Ioannou
2000). Some of the conserved cysteines in this region
have been shown to be critical for normal NPC1 func-
tion by transfection of cysteinerserine NPC1 mutant
constructs into NPC1 deficient cells (Watari et al. 2000).
In a study of NPC1 mutations in patients from 13 ap-
parently unrelated families, Greer et al. (1999) noted a
prevalence of missense mutations within the cysteine-
rich region and interpreted this as evidence that this
region is critical for NPC function. Our observations
suggest that mutations in this region may be associated
with either a variant phenotype (e.g., D948N, S1004L,
R978C, or R958Q), a classical phenotype (e.g., D874V,
P888S, L929P, or C976R), or either phenotype (e.g.,
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S940L and P1007A). For those mutations that are found
in association with both phenotypes, we propose that
it is the second mutation that primarily determines the
cell phenotype. Thus, we suggest that R978C, R958Q,
and IVS21(-10)delTCC are biochemically mild muta-
tions and that D242N and 688del6bp are biochemically
severe mutations. From our study, the relative roles that
specific NPC1 mutations, other genetic factors, and
nongenetic factors play in determining phenotype can-
not be determined with certainty. However, evidence for
NPC1 genotype influence on phenotype is provided by
the observation that four pairs of siblings (in which each
sib pair showed identical mutations) were classified con-
cordantly as having either the variant or the classical
phenotype (table 2).
One recurrent mutation (P237S) reported here is wor-
thy of note. This point mutation occurred in both var-
iant and classical samples in the present study (table 2)
and was reported elsewhere to be a deleteriousmutation
with no occurrence in 100 normal samples (Yamamoto
et al. 2000). However, we have identified this substi-
tution in 2 of 98 chromosomes in a screen of 49 an-
onymized samples from the general population (K.S.,
unpublished data). In addition, we have identified sev-
eral NPC fibroblast samples that have two mutations,
in addition to the P237S substitution (sample C20 in
table 2 and data not shown). On the basis of these
observations, we believe that the P237S substitution is
more likely to be a benign polymorphism than a dele-
terious mutation, although we cannot rule out the pos-
sibility that it could have a modifying effect on NPC1
function. This uncertainty could be resolved by exam-
ination of the phenotype of NPC null cells transfected
with a NPC1-P237S mutation construct.
All the cell samples studied here were from patients
whose clinical symptoms were consistent with a diag-
nosis of NPC. We classified samples as NPC variants
solely on the basis of relatively higher esterification rates
and nondefinitive filipin staining. From the limited clin-
ical data we have available for the NPC cell lines stud-
ied, we found cases of juvenile- and adult-onset disease
among both variant and classical biochemical pheno-
types. Postmortem histological analysis of individual
cases also showed similar brain pathology for variant
versus classical patients. Our data thus suggested no
distinction on clinical grounds between the variant and
classic biochemical phenotypes. We found that 5 of 12
of the unique variant patient samples possessed no
detectable defect in the NPC1 protein, although we
screened by CSGE and fully sequenced all NPC1 exons
in these samples, and, clinically, the patients fromwhich
these cells were derived presented with typical NPC
symptoms (e.g., vertical supranuclear gaze palsy, de-
mentia and movement disorders). Preliminary immu-
nofluorescence studies using a polyclonal antibody
against the C-terminus of the NPC1 protein showed a
level of NPC1 expression in all variant samples (both
with and without NPC1 mutations) at least as high as
that in normal fibroblasts (data not shown). Thus, we
have no evidence for regulatory NPC1 mutations lead-
ing to a lower expression of NPC1 in the non-NPC1
variant patients. Interestingly, our immunofluorescence
studies are consistent with a recent report which showed
that a high level of NPC1 expression (determined by
western blotting) was typical of patients in the NPC1
complementation group who had a less severe clinical
phenotype (Yamamoto et al. 2000). Except in one case,
where a cell line was identified as NPC2, complemen-
tation studies to classify these samples as either NPC1
or NPC2 were found to be impractical in these cell lines
because of low levels of filipin staining. Future studies
will be required to determine if any of these other cell
samples lacking in mutations in NPC1 are defective in
HE1, the newly identified NPC2 gene product (Nau-
reckiene et al. 2000) or are the result of a different
disorder that has overlapping clinical and biochemical
features with NPC.
In conclusion, we have developed an assay, based on
the altered intracellular trafficking of BODIPY-LacCer,
that can be used to detect NPC variants. All variant
NPC fibroblast samples tested responded to an LDL-
cholesterol challenge, distinguishing them from normal
fibroblasts and demonstrating that these patient samples
do possess a reduced ability to handle free cholesterol,
which is consistent with their inclusion in the NPC dis-
ease category. Finally, by NPC1 mutation analysis, we
found that most variant samples could be placed in one
of two categories: those having mutation(s) present
within the cysteine-rich region of NPC1 and those in
which no NPC1 mutation was detected. These data pro-
vide a new technique which may be useful for the di-
agnosis of NPC variants, and lend new insight into the
function of the NPC1 protein.
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